Karuna Therapeutics
ClosedPushing the boundaries of neuroscience to transform the treatment of mental illness
Boston, United States · Founded 2018 · $12.0M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- karunatx.com
- Total Funding
- $12.0M
- Last Round
- $12.0M Extension RoundApr 2019
- Rounds
- 1
About
Karuna Therapeutics was a clinical-stage biopharmaceutical company developing novel muscarinic receptor modulators for the treatment of schizophrenia, Alzheimer's disease psychosis, and other psychiatric conditions. Its lead candidate, KarXT (xanomeline-trospium), received FDA approval as Cobenfy — the first new schizophrenia mechanism in decades. Karuna was founded in 2018 as a PureTech Health company and was acquired by Bristol Myers Squibb in March 2024 for $14 billion, representing one of the largest neuroscience acquisitions in pharmaceutical history.
Summary
Karuna Therapeutics is a Life Sciences company based in Boston, United States, founded in 2018. It has raised $12.0M in total across 1 round, most recently a $12.0M Extension Round round in Apr 2019.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2019
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...